Diabetes Clinical Trials Network (DCTN)

Members of the DCTN have been involved in almost all of the major international diabetes trials conducted over the last decade as designers, leaders, coordinators, and/or recruiters. These include the effect of three landmark trials of more versus less intense glucose lowering effects on clinical outcomes (the DCCT in type 1 diabetes, and the ACCORD and ADVANCE trial in type 2 diabetes), more than 40 large landmark outcomes trials of glucose, lipid, and blood pressure therapies in type 2 diabetes, trials of type 2 diabetes remission, and many trials of insulin pump therapy and the artificial pancreas in type 1 diabetes. Collectively these trials have changed diabetes, lipid and blood pressure guidelines and indeed the whole approach to the care of type 1 and type 2 diabetes. The DCTN is chaired by Dr. Hertzel Gerstein, Senior Scientist and Deputy Director, PHRI.

The Accelerating Clinical Trials Consortium is generously supported through multi-year funding from the Canadian Institutes of Health Research’s Clinical Trials Fund, as part of Canada’s Biomanufacturing and Life Sciences Strategy to ensure that Canadians are well served by a national clinical trials network.